VBI Vaccines (OTCPK:VBIV.Q) - 주가, 뉴스 및 분석

VBIV.Q 주식 개요

상용 단계의 바이오 제약 회사인 VBI 백신은 면역 종양학 및 전염병 치료를 위한 백신을 개발 및 판매합니다. 자세한 내용

VBIV.Q 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	2/6
배당금	0/6

위험 분석

의미 있는 시가총액이 없습니다. ( $14K )

마이너스 주주 지분

지난 5년간 매년 수익이 17.4% 씩 감소했습니다.

최근 3개월간 주가 변동폭 심해

+ 1 더 많은 위험

VBI Vaccines Inc. 경쟁사

TRACON Pharmaceuticals

OTCPK:TCON

US$100.5k

ObsEva

OTCPK:OBSE.F

US$11.7k

Comera Life Sciences Holdings

OTCPK:CMRA

US$6.1k

Genocea Biosciences

OTCPK:GNCA.Q

US$5.9k

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 VBI Vaccines
과거 주가
현재 주가	US$0.0005
52주 최고치	US$1.35
52주 최저치	US$0.0002
베타	2.22
11개월 변경	0%
3개월 변경 사항	-97.01%
1년 변경 사항	-99.92%
33년 변화	-100.00%
5년 변화	-100.00%
IPO 이후 변화	-100.00%

최근 뉴스 및 업데이트

Recent updates

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

Jan 24

주주 수익률

	VBIV.Q	US Biotechs	US 마켓
7D	0%	4.0%	2.0%
1Y	-99.9%	18.0%	32.4%

수익률 대 산업: VBIV.Q 지난 1년 동안 18 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: VBIV.Q 지난 1년 동안 32.4 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is VBIV.Q's price volatile compared to industry and market?
VBIV.Q volatility
VBIV.Q Average Weekly Movement	52.0%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

안정적인 주가: VBIV.Q 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: VBIV.Q 의 주간 변동성은 지난 1년 동안 36% 에서 52% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
n/a	135	Jeff Baxter	www.vbivaccines.com

상용 단계의 바이오 제약 회사인 VBI 백신은 면역 종양학 및 전염병 치료를 위한 백신을 개발 및 판매합니다. 프리헤브리오, 프리헤브리, Sci-B-Vac이라는 브랜드명으로 B형 간염(HBV) 백신을 제공합니다. 또한 만성 HBV 감염 치료를 위한 단백질 기반 면역치료 후보물질인 VBI-2601, 교모세포종 암 백신 면역치료 후보물질인 VBI-1901, 예방적 거대세포바이러스 백신 후보물질인 VBI-1501, 지카 바이러스 치료용 VBI-2501을 개발하고 있습니다.

VBI Vaccines Inc. 기본 사항 요약

VBI Vaccines 의 수익과 매출은 시가총액과 어떻게 비교하나요?
VBIV.Q 기본 통계
시가총액	US$14.34k
수익(TTM)	-US$83.99m
수익(TTM)	US$9.41m

0.0x

P/S 비율

0.0x

P/E 비율

VBIV.Q 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
VBIV.Q 손익 계산서(TTM)
수익	US$9.41m
수익 비용	US$11.67m
총 이익	-US$2.26m
기타 비용	US$81.73m
수익	-US$83.99m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.93
총 마진	-24.03%
순이익 마진	-892.47%
부채/자본 비율	-891.6%

VBIV.Q 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

VBIV.Q 주식 개요

위험 분석

VBI Vaccines Inc. 경쟁사

OTCPK:TCON

US$100.5k

OTCPK:OBSE.F

US$11.7k

OTCPK:CMRA

US$6.1k

OTCPK:GNCA.Q

US$5.9k

가격 내역 및 성능

최근 뉴스 및 업데이트

VBI Vaccines Inc. Issues Voluntary Nationwide Recall of All PreHevbrio Vaccine Due to Discontinuation of Company Operations

The Nasdaq Stock Market to Delist Ordinary Shares of VBI Vaccines

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

Recent updates

VBI Vaccines Inc. Issues Voluntary Nationwide Recall of All PreHevbrio Vaccine Due to Discontinuation of Company Operations

The Nasdaq Stock Market to Delist Ordinary Shares of VBI Vaccines

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc. announced delayed annual 10-K filing

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Consensus revenue estimates increase by 291%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Consensus EPS estimates upgraded to US$4.46 loss

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 21% undervalued after recent price drop

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 1,377%

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Consensus revenue estimates fall by 32%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat